Finally, ecto-TMEM219 was tested in a diabetes reversal NOD mouse model, in which hyperglycemic NOD mice were treated with ecto-TMEM219 within 24 h from the onset of hyperglycemia and demonstrated preserved blood glucose levels, with 25% of mice remaining normoglycemic until the completion of the study at day 20 (Fig. 5p, q), and no detectable islet infiltration/inflammation (Fig. 5r). Here, TMEM219 is linked to Hyperglycemia.